CN115491322B - 一类生物碱的提取方法与应用 - Google Patents
一类生物碱的提取方法与应用 Download PDFInfo
- Publication number
- CN115491322B CN115491322B CN202210562230.1A CN202210562230A CN115491322B CN 115491322 B CN115491322 B CN 115491322B CN 202210562230 A CN202210562230 A CN 202210562230A CN 115491322 B CN115491322 B CN 115491322B
- Authority
- CN
- China
- Prior art keywords
- compound
- compounds
- methanol
- component
- streptomyces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 9
- 238000000605 extraction Methods 0.000 title description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 96
- 241000187747 Streptomyces Species 0.000 claims abstract description 25
- 241000946755 Streptomyces tanashiensis Species 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 238000004321 preservation Methods 0.000 claims abstract description 14
- 241000192043 Echinochloa Species 0.000 claims abstract description 13
- 241000282414 Homo sapiens Species 0.000 claims abstract description 12
- 230000002786 root growth Effects 0.000 claims abstract description 12
- 238000000855 fermentation Methods 0.000 claims abstract description 11
- 230000004151 fermentation Effects 0.000 claims abstract description 11
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims abstract description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 7
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 7
- 201000001441 melanoma Diseases 0.000 claims abstract description 7
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 7
- -1 alkaloid compound Chemical class 0.000 claims abstract description 6
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 108
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 55
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000002609 medium Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 229940125782 compound 2 Drugs 0.000 claims description 7
- 229940126214 compound 3 Drugs 0.000 claims description 7
- 239000003480 eluent Substances 0.000 claims description 7
- 238000004440 column chromatography Methods 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 229940125904 compound 1 Drugs 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229940125898 compound 5 Drugs 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 claims description 3
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 claims description 3
- 244000038561 Modiola caroliniana Species 0.000 claims description 3
- 235000010703 Modiola caroliniana Nutrition 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 230000011218 segmentation Effects 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 229940125773 compound 10 Drugs 0.000 claims description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims 2
- 239000003560 cancer drug Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 9
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 241000194048 Streptococcus equi Species 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 239000004009 herbicide Substances 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- PAYLFJFRBIHGBV-UHFFFAOYSA-N 2-amino-5-(2-hydroxyanilino)-3,6-dioxocyclohexa-1,4-diene-1-carboxamide Chemical compound O=C1C(C(=O)N)=C(N)C(=O)C=C1NC1=CC=CC=C1O PAYLFJFRBIHGBV-UHFFFAOYSA-N 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000005100 correlation spectroscopy Methods 0.000 description 8
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 8
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 8
- AUBMZQABQDPFKS-UHFFFAOYSA-N n-[8-(hydroxymethyl)-3-oxophenoxazin-2-yl]acetamide Chemical compound OCC1=CC=C2OC3=CC(=O)C(NC(=O)C)=CC3=NC2=C1 AUBMZQABQDPFKS-UHFFFAOYSA-N 0.000 description 8
- 229930000044 secondary metabolite Natural products 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 239000008223 sterile water Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241001655322 Streptomycetales Species 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 150000001793 charged compounds Chemical class 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 3
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001536358 Fraxinus Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000002611 lead compounds Chemical class 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010183 spectrum analysis Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 2
- 240000001606 Adenanthera pavonina Species 0.000 description 2
- 235000011470 Adenanthera pavonina Nutrition 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241001537924 Tetracoccus <angiosperm> Species 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- HXKWSTRRCHTUEC-UHFFFAOYSA-N 2,4-Dichlorophenoxyaceticacid Chemical compound OC(=O)C(Cl)OC1=CC=C(Cl)C=C1 HXKWSTRRCHTUEC-UHFFFAOYSA-N 0.000 description 1
- 241000203809 Actinomycetales Species 0.000 description 1
- 244000237956 Amaranthus retroflexus Species 0.000 description 1
- 235000013479 Amaranthus retroflexus Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000256602 Isoptera Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- WGCOQYDRMPFAMN-ZDUSSCGKSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyrimidin-5-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=NC=1 WGCOQYDRMPFAMN-ZDUSSCGKSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
- A01N37/22—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof the nitrogen atom being directly attached to an aromatic ring system, e.g. anilides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/84—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms six-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,4
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N55/00—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
- A01N55/02—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing metal atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
- C07C233/33—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/38—[b, e]-condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/008—Preparation of nitrogen-containing organic compounds containing a N-O bond, e.g. nitro (-NO2), nitroso (-NO)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/14—Nitrogen or oxygen as hetero atom and at least one other diverse hetero ring atom in the same ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及微生物工程技术领域,具体涉及从黑翅土白蚁体表链霉菌(Streptomyces tanashiensis)BYF112的液体发酵物中提取的一类生物碱化合物及其制备方法和应用。具体而言,本发明公开11种生物碱类化合物,其结构式为:其中化合物1,2,3和7为新化合物。该生物碱类化合物能通过保藏号为CCTCC M 2019474的链霉菌(Streptomyces tanashiensis)BYF112制备而得。该生物碱类化合物1、2、5、6、10、11能作为抗癌药物,具体为化合物2、5、6、10、11能抑制人恶性黑色素瘤细胞(A375),化合物1、5、6、11能抑制卵巢癌细胞(SKOV‑3)生长,化合物5、6、10、11能抑制人胃癌细胞(MGC‑803)生长;化合物11可作为抗菌剂,具体为能抑制四链球菌生长;化合物5和11可作为除草剂,具体为能抑制稗草根的生长。
Description
技术领域
本发明涉及微生物技术领域,具体涉及从黑翅土白蚁体表链霉菌(Streptomycestanashiensis)BYF112液体发酵物中提取一类生物碱的制法和应用。
背景技术
目前,临床所用的大部分化疗药物毒副作用大,且肿瘤细胞受本身的耐药性及外界药物的影响,出现大量肿瘤多药耐药细胞株,致使化疗药物疗效大打折扣;另一方面,由于抗生素滥用现象日益严重,导致临床上原本有特效的抗生素对耐药菌作用越来越小。若该现象不能得以改善,将对全球医疗卫生安全构成极大威胁。因此,寻找新型具有抗肿瘤或抗生素活性的先导化合物迫在眉睫。
随着人们对合成化学药品毒副作用的深入认识及全球范围内提倡回归自然的态度,国际上对天然药物的重视程度在不断加强,并且天然药物具有高效低毒的特点,故而天然药物是未来药物发展的大趋势。
链霉菌属是放线菌目中最庞大的成员,为革兰氏阳性、好氧、丝状菌,广泛分布于自然环境中,产生多种生物活性的次级代谢产物,如抗生素、维生素、酶抑制剂等。据统计,临床抗生素有60%以上来自链霉菌。近年来研究发现昆虫共生菌特殊生境中的链霉菌具有代谢产物特殊、化学结构新颖、生物活性强等作为药用资源的巨大潜力。例如,从一株假单胞菌分离出一种新的双吲哚类抗癌药雷贝卡霉素(Van Arnam,E.B.;Ruzzini.A.C.;Sit,C.S.;Horn,H.;Pinto-T,A.A.;Currie,C.R.;Clardy,J.J.Am.Chem.Soc.2015,137,14272-14274.)。
发明内容
本发明要解决的技术问题是提供一种黑翅土白蚁共生链霉菌(Streptomycestanashiensis)BYF112及其产生的具有抗癌活性化合物的制备与用途-作为一种抗癌先导化合物。
为了解决上述技术问题,本发明提供链霉菌产生的具有抗癌活性化合物,其结构式为:
本发明还同时提供了一株具有强力抗癌活性的链霉菌BYF-112,保藏号为CCTCCM2019474,保藏日期为2019年06月20日,保藏地址为中国典型培养物保藏中心(CCTCC)湖北省武汉市武昌区八一路珞珈山。
本发明还同时提供了上述新吩嗪抗癌活性代谢产物制备方法,包括如下步骤:
1)、保藏号为CCTCC M 2019474的链霉菌BYF-112接种到高氏培养基上,于摇床上,在160~200rpm(较佳为180rpm)、27.5~28.5℃(较佳为28℃)条件下培养2~3天作为种子液;
2)、将种子液接种于高氏培养基中,在160~200rpm(较佳为180rpm)27.5~28.5℃(较佳为28℃)条件下发酵6.5~7.5天(较佳为7天);
一般而言,每10mL种子液接种于350~450mL(较佳为400ml的高氏培养基中);
3)、将步骤2)所得发酵液过滤(经两层纱布过滤),滤液用乙酸乙酯萃取(共萃取3次,每次乙酸乙酯的用量=发酵液的体积量),真空浓缩干燥(于0.1个负压的真空度,45℃干燥30-50分钟),得浸膏(呈黑色);
4)、将步骤3)所得浸膏进行硅胶柱层析分段,采用二氯甲烷/甲醇进行梯度洗脱,所述二氯甲烷与甲醇的体积比依次为100:0、100:1、100:2、100:4、100:8;从而分别得到5个洗脱部分F1-F5;
5)、将步骤4)所得组分F2干燥处理后,在甲醇中重结晶,经TLC分析得到化合物8。
6)、将步骤4)所得组分F3干燥处理后,在甲醇中重结晶,经TLC分析得到化合物11和组分F3-1,将组分F3-1干燥后,在乙酸乙酯中重结晶,经TLC分析分别得到化合物5和10和组分F3-1-1,将组分F3-1-1经凝胶柱层析分离,以甲醇为洗脱剂,经TLC分析得到化合物2。
7)、将步骤4)所得组分F4干燥处理后,在甲醇中重结晶,经TLC分析得到化合物9和组分F4-1,F4-2,F4-3,F4-4,将组分F4-1和F4-2合并经凝胶柱层析分离,以甲醇为洗脱剂,经TLC分析分别得到化合物1,6和7;将组分F4-3采用采用二氯甲烷/甲醇进行梯度洗脱,所述二氯甲烷与甲醇的体积比依次为100:0、100:1、50:1、20:1、10:1;将二氯甲烷与甲醇的体积比为10:1干燥处理后,在甲醇中重结晶,经TLC分析得到化合物3;将组分F4-4采用二氯甲烷/甲醇进行梯度洗脱,所述二氯甲烷与甲醇的体积比依次为100:0、100:1、100:2、100:4、100:8,将二氯甲烷与甲醇的体积比为100:4干燥处理后,在甲醇中重结晶,经TLC分析得到化合物4。
进一步的,步骤(1)中,将链霉菌(Streptomyces tanashiensis)BYF-112经高氏培养基活化后接种于高氏液体培养基中发酵培养6.5~7.5d,温度为27.5~28.5℃(较佳为28℃),转速为160~200rpm(较佳为180rpm)。
本发明所使用的高氏液体培养基为,20g可溶性性淀粉,0.5g KNO3,0.5g K2HPO4·3H2O,0.5g MgSO4·7H2O,0.5g NaCl,0.01g FeSO4·7H2O g,用蒸馏水配制1L,pH 7.0~8.0。
本发明还同时提供了上述次级代谢产物在抗癌方面的应用,所述化合物可作为制备的抗肿瘤、抗菌、除草的药物。
上述化合物可作为抑制黑色素细胞瘤、胃癌、乳腺癌和卵巢癌细胞生长、抑制四链球菌生长、抑制稗草根生长的药物。
本发明所述链霉菌,链霉菌的分类学命名为Streptomyces tanashiensis BYF-112,分离于中国江苏江阴郊区,该菌株于2019年6月20日保藏于中国典型培养物保藏中心,保藏编号为CCTCC M 2019474。保藏单位地址为中国.武汉。
本发明具有如下有益效果:
1.本发明的链霉菌BYF-112次级代谢产物(1-4和7)是新化合物,(5-6,8-11)是已知物,可以作为具有抑制黑色素细胞瘤、胃癌、乳腺癌和卵巢癌细胞生长、抑制四链球菌生长、抑制稗草根生长的先导化合物。
2.本发明的链霉菌BYF-112次级代谢产物可以利用微生物进行液体发酵生产,工艺简便,周期短,成本低,来源有保证。
3.本发明利用生物法合成链霉菌BYF-112次级代谢产物对环境无污染。
保藏信息
保藏时间:2019年6月20日
保藏单位:中国典型培养物保藏中心;
保藏编号:CCTCC M 2019474;
保藏单位地址:中国典型培养物保藏中心(CCTCC)湖北省武汉市武昌区八一路珞珈山武汉大学;
分类命名:Streptomyces tanashiensis BYF-112。
附图说明
图1为本发明实施例提供的11种生物碱类化合物的结构式。
图2为本发明实施例提供的化合物vegfrecine A(1)的1H NMR(Agilent DD2,DMSO-d6.)光谱图。
图3为本发明实施例提供的化合物vegfrecine A(1)的13C NMR(Agilent DD2,DMSO-d6.)光谱图。
图4为本发明实施例提供的化合物vegfrecine A(1)的COSY(Agilent DD2,DMSO-d6.)光谱图。
图5为本发明实施例提供的化合物vegfrecine A(1)的HSQC(Agilent DD2,DMSO-d6.)光谱图。
图6为本发明实施例提供的化合物vegfrecine A(1)的DEPT(Agilent DD2,DMSO-d6.)光谱图。
图7为本发明实施例提供的化合物vegfrecine A(1)的HMBC(Agilent DD2,DMSO-d6.)光谱图。
图8为本发明实施例提供的化合物vegfrecine A(1)的HR-ESI-MS图。
图9为本发明实施例提供的化合物vegfrecine B(2)的1H NMR(Agilent DD2,Actone-d6.)光谱图。
图10为本发明实施例提供的化合物vegfrecine B(2)的13C NMR(Agilent DD2,Actone-d6.)光谱图。
图11为本发明实施例提供的化合物vegfrecine B(2)的COSY(Agilent DD2,Actone-d6.)光谱图。
图12为本发明实施例提供的化合物vegfrecine B(2)的HSQC(Agilent DD2,Actone-d6.)光谱图。
图13为本发明实施例提供的化合物vegfrecine B(2)的DEPT(Agilent DD2,Actone-d6.)光谱图。
图14为本发明实施例提供的化合物vegfrecine B(2)的HMBC(Agilent DD2,Actone-d6.)光谱图。
图15为本发明实施例提供的化合物vegfrecine B(2)的HR-ESI-MS图。
图16为本发明实施例提供的化合物exfoliazone A(3)的1H NMR(Agilent DD2,DMSO-d6.)光谱图。
图17为本发明实施例提供的化合物exfoliazone A(3)的13C NMR(Agilent DD2,DMSO-d6.)光谱图。
图18为本发明实施例提供的化合物exfoliazone A(3)的COSY(Agilent DD2,DMSO-d6.)光谱图。
图19为本发明实施例提供的化合物exfoliazone A(3)的HSQC(Agilent DD2,DMSO-d6.)光谱图。
图20为本发明实施例提供的化合物exfoliazone A(3)的DEPT(Agilent DD2,DMSO-d6.)光谱图。
图21为本发明实施例提供的化合物exfoliazone A(3)的HMBC(Agilent DD2,DMSO-d6.)光谱图。
图22为本发明实施例提供的化合物exfoliazone A(3)的HR-ESI-MS图。
图23为本发明实施例提供的化合物venezueline H(7)的1H NMR(Agilent DD2,DMSO-d6.)光谱图。
图24为本发明实施例提供的化合物venezueline H(7)的13C NMR(Agilent DD2,DMSO-d6.)光谱图。
图25为本发明实施例提供的化合物venezueline H(7)的COSY(Agilent DD2,DMSO-d6.)光谱图。
图26为本发明实施例提供的化合物venezueline H(7)的HSQC(Agilent DD2,DMSO-d6.)光谱图。
图27为本发明实施例提供的化合物venezueline H(7)的HMBC(Agilent DD2,DMSO-d6.)光谱图。
图28为本发明实施例提供的化合物venezueline H(7)的HMBC(Agilent DD2,DMSO-d6.)光谱图。
图29为本发明实施例提供的化合物venezueline H(7)的HR-ESI-MS图。
图30为本发明实施例提供的化合物对稗草根的生长抑制测定结果
具体实施方式
为了更好的理解本发明的内容,下面结合具体实施例进一步说明,但本专利的保护内容不仅限于此。
下面结合具体实施例对本发明做进一步的解释。
实施例1:链霉菌(Streptomyces tanashiensis)BYF-112分离与纯化链霉菌BYF-112的分离:
分离前让黑翅土白蚁饥饿24h,用无菌镊子分别取出年轻工蚁(20头)置于灭菌离心管中。加入1mL pH7.4的无菌PBS缓冲液,震荡得到漂洗液。用无菌水对震荡液梯度稀释成10-1、10-2、10-3,分别取各梯度稀释液0.1mL涂布于M3培养基平板上,28℃恒温箱中培养4天。待菌落长出后,从组织块菌落边缘挑取少量菌丝,再次转接高氏培养基平板上,经纯化得到单菌落,经形态学与分子生物学鉴定为田无链霉菌(Streptomyces tanashiensis)BYF-112
培养基:20g可溶性性淀粉,0.5g KNO3,0.5g K2HPO4·3H2O,0.5g MgSO4·7H2O,0.5g NaCl,0.01g FeSO4·7H2O,用蒸馏水配制1L,pH 7.0~8.0,1.1个大气压,121℃下灭菌20min(为常规灭菌)。
上述链霉菌(Streptomyces tanashiensis)BYF-112进行了保藏,保藏单位:中国典型培养物保藏中心;保藏名称为:Streptomyces tanashiensis BYF-112,保藏地址:中国武汉,武汉大学;保藏日期:2019.06.20;保藏号为CCTCC M 2019474。
上述链霉菌(Streptomyces tanashiensis)BYF-112可接种至高氏斜面试管保存备用。
实施例2:昆虫共生菌--田无链霉菌(Streptomyces tanashiensis)BYF-112的液体发酵
将新鲜的链霉菌(Streptomyces tanashiensis)BYF-112的菌丝体块(约2~3g)接种到250mL锥形瓶中,每瓶含有150mL的高氏培养基,接种10~15瓶于摇床上,在180rpm、28℃条件下培养2~3天作为种子液,然后将10mL种子液接种于装有400mL的高氏培养基的1000mL锥形瓶中,在180rpm、28℃条件下发酵7天。
备注说明:田无链霉菌(Streptomyces tanashiensis)BYF-112经常规的高氏培养基活化后,即可得新鲜的田无链霉菌(Streptomyces tanashiensis)BYF-112。
所述高氏培养基的配方为:20g可溶性性淀粉,0.5g KNO3,0.5g K2HPO4·3H2O,0.5g MgSO4·7H2O,0.5g NaCl,0.01g FeSO4·7H2O,用蒸馏水配制1L,pH 7.0~8.0,1.1个大气压,121℃下灭菌20min(为常规灭菌)。
实施例3、链霉菌BYF-112次级代谢产物的提取与分离
将实施例2制备而得的15.6L发酵液经两层纱布过滤,滤液用乙酸乙酯萃取3次(乙酸乙酯每次的用量为50L),所得的萃取液真空浓缩干燥(于0.1个负压的真空度,45℃干燥30-50分钟)得黑色浸膏。对该浸膏进行硅胶柱层析分段(所述硅胶柱选用200~300目的硅胶,重量为200g),所述二氯甲烷与甲醇的体积比依次为100:0、100:1、100:2、100:4、100:8;从而分别得到5个洗脱部分F1-F5;每种洗脱液的用量分别为2700~3000、1200~1400、5600~5900、2000~2300、1200~1500、1800~2000、800~1200ml;从而分别得到5个洗脱部分F1-F5;
将所得组分F2干燥处理后,在甲醇中重结晶,经TLC分析得到化合物8。所得组分F3干燥处理后,在甲醇中重结晶,经TLC分析得到化合物11和组分F3-1,将组分F3-1干燥后,在乙酸乙酯中重结晶,经TLC分析分别得到化合物5和10和组分F3-1-1,将组分F3-1-1经凝胶柱层析分离,以甲醇为洗脱剂,经TLC分析得到化合物2。将所得组分F4干燥处理后,在甲醇中重结晶,经TLC分析得到化合物9和组分F4-1,F4-2,F4-3,F4-4,将组分F4-1和F4-2合并经凝胶柱层析分离,以甲醇为洗脱剂,经TLC分析分别得到化合物1,6和7;将组分F4-3采用采用二氯甲烷/甲醇进行梯度洗脱,所述二氯甲烷与甲醇的体积比依次为100:0、100:1、50:1、20:1、10:1;将二氯甲烷与甲醇的体积比为10:1干燥处理后,在甲醇中重结晶,经TLC分析得到化合物3;将组分F4-4采用二氯甲烷/甲醇进行梯度洗脱,所述二氯甲烷与甲醇的体积比依次为100:0、100:1、100:2、100:4、100:8,将二氯甲烷与甲醇的体积比为100:4干燥处理后,在甲醇中重结晶,经TLC分析得到化合物4。
其结构式为:
实施例4田无链霉菌BYF-112代谢产物的结构解析
化合物1为紫红色粉末,HR-ESI-MS在m/z 323.0642[M+Na]+处给出分子离子峰(如图8所示),推测化合物的分子式为C15H12N2O5。对该化合物的1H-NMR(如图2所示)和13C-NMR谱图(如图3所示)分析发现该化合物与Vegfrecine具有相同的母核结构,通过二维HSQC(如图5所示)、COSY(如图4所示)和HMBC(如图7所示)的谱图分析,最终确定化合物的结构如式(1)中所示。化合物1命名为VegfrecineA(1),该化合物的1H和13C NMR(DMSO-d6)归属如表1所示。
化合物2为紫红色粉末,HR-ESI-MS在m/z 325.0975[M+Na]+处给出分子离子峰(如图15所示),推测化合物的分子式为C15H14N2O5。对该化合物的1H-NMR(如图9所示)和13C-NMR谱图(如图10所示)分析发现与化合物1具有相同的母核结构,唯一区别是苯环5,被氧化成醛基。通过二维HSQC(如图12所示)、COSY(如图11所示)和HMBC(如图14所示)的谱图分析,最终确定化合物的结构如式(1)中所示。化合物2命名为VegfrecineB(2),该化合物的1H和13C-NMR(Acetone-d6)归属如表1所示。
化合物3为红色固体,HR-ESI-MS在m/z 257.0930[M+H]+处给出分子离子峰(如图22所示),推测化合物的分子式为C14H12N2O3。对该化合物的1H-NMR(如图16所示)和13C-NMR谱图(如图17所示)分析发现该化合物与Exfoliazone具有相同的母核结构,通过二维HSQC(如图19所示)、COSY(如图18所示)和HMBC(如图21所示)的谱图分析,最终确定化合物的结构如式(1)中所示。化合物3命名为Exfoliazone A(3),该化合物的1H和13C NMR(DMSO-d6)归属如表2所示。
化合物7为红色粉末,HR-ESI-MS在m/z 470.1320[M+Na]+处给出分子离子峰(如图29所示),推测化合物的分子式为C24H21N3O6。对该化合物的1H-NMR(如图23所示)和13C-NMR谱图(如图24所示)分析发现该化合物与Venezueline具有相同的母核结构,通过二维HSQC(如图26所示)、COSY(如图25所示)和HMBC(如图28所示)的谱图分析,最终确定化合物的结构如式(1)中所示。化合物7命名为VegfrecineA(7),该化合物的1H和13C NMR(DMSO-d6)归属如表3所示。
表1化合物1(VegfrecineA,DMSO-d6)和2(VegfrecineB,Acetone-d6)的1H和13CNMR归属
表2化合物3(ExfoliazoneA)的1H和13CNMR(DMSO-d6)归属.
表3化合物7(Venezueline H)的1H和13CNMR(DMSO-d6)归属.
实施案例5化合物的细胞毒性活性测定
细胞培养细胞培养于含10%胎牛血清的DMEM培养基中,置于37℃、5%二氧化碳胞培养箱中培养,稳定传2~3代后,取对数生长期的细胞做后续实验。
细胞增殖实验收集对数期细胞,计数,调整细胞悬液浓度,以4000个/100μl/孔,接种于96孔板,37℃、5%二氧化碳条件下培养24h后至细胞单层铺满孔底面积的2/3。从孔边缘小心吸弃培养基,各加入一定浓度梯度的化合物,100μl/孔,每组设4个平行复孔,分别培养24、48、72h。避光条件下,加入MTT溶液20μl/孔,继续放入培养箱中培养4h。小心吸去孔内培养液,加入DMSO,150μl/孔,置摇床上低速振荡15min。在酶标仪492nm处测量各孔的吸光度值(optical density,OD),以对照孔调零。记录结果并计算细胞抑制率,抑制率(Inhibitory concentration,IC)(%)=(1-(实验组OD均值-空白组OD均值)/(对照组OD均值-空白组OD均值]×100%,实验重复操作3次,并计算均值和半数抑制浓度(IC50)。阳性对照为阿霉素(Adriamycin),空白对照为溶剂处理的肿瘤细胞.
表4链霉菌BYF-112次级代谢产物的IC50
阿霉素:阳性对照。b:未测试。C:浓度>100μm。A375:人恶性黑色素瘤细胞。SKOV-3,人卵巢癌细胞。MDA-MB231:人乳腺癌细胞。MGC-803:人胃癌细胞。L-02:正常细胞。
如表4所示,新化合物1中对SKOV-3IC50值为76.18±2.09μM,与阳性对照0.72±0.12μM相比,细胞毒活性极弱,但对正常细胞的毒活性也很弱;新化合物2对A375 IC50值为47.25±0.98μM,与阳性对照1.01±0.48μM相比,细胞毒活性较弱,但强于化合物1对SKOV-3的细胞毒活性,对正常细胞毒活性也很弱;新化合物3对四种细胞株毒性较弱。化合物5、6、11对A375表现出显著活性,IC50值分别为7.32、5.85、5.46和8.20μM,与阳性对照IC50=1.01μM相当,同时,化合物11对正常细胞(L-02)没有毒性。此外,化合物5、6对SKOV-3表现出较好毒活性,IC50值为6.09-11.09μM,与阳性对照阿霉素IC50值0.72±0.12μM细胞毒活性相当。化合物6,8,9,10对A375有一定活性,IC50值为22.01±0.38μM,与阳性对照1.01±0.48μM相比,活性一般。单体8,9对四种细胞株的活性都比较弱。
实施案例6化合物的抑菌活性测定
采用滤纸片扩散法检测化合物对四联球菌(Mlicrococcus tetragenus),将化合物和硫酸庆大霉素(阳性对照)用丙酮溶解浓度为6mg/mL的溶解液,用0.22μm的有机相微孔滤膜过滤除菌。用划线法将四联球菌(Mlicrococcus tetragenus)接种至LB固体培养基中,置于37℃恒温培养24h活化。取1mL无菌水于1.5mL离心管中,用接种环蘸取少量细菌于无菌水中混合均匀制成菌悬液,比对比浊管将菌悬液浓度调整为约106cfμ/mL,然后用孔直径为6mm的单孔打孔机将滤纸打成若干滤纸圆片灭菌备用。取100μL菌悬液加入100mL 50-60℃LB固体培养基中混合均匀倒平板,待培养基凝固后,将无菌滤纸小心贴在培养基上,每滤纸片滴加5μL的代谢产物或硫酸庆大霉素,最后置于37℃恒温培养24h,十字交叉法测量抑菌圈直径,每组三个重复
表5链霉菌BYF-112次级代谢产物11对四链球菌抑菌圈直径(mm)
测定结果如表5所示,在供试浓度为30μg时化合物11对Mlicrococcus tetragenus抑菌圈平均直径为14.1mm,与阳性对照硫酸庆大霉素28.0mm相比具有中等的抑菌能力。
实施案例7化合物对稗草根生长抑制测定
采用滤纸-培养皿法测定化合物对稗草根生长的抑制活性。采用滤纸-培养皿法测定粗浸膏对反枝苋及常见农作物根生长的抑制活性。具体操作如下:(1)用次氯酸钠浸泡稗草15min,清水洗涤2-3次。将处理过的上述种子置于含水的滤纸-培养皿中,光照培养箱(27℃、80%相对湿度,12/12白天/黑夜)中催芽1d,去除浮于水面的种子,剩余的种子用蒸馏水冲洗干净,备用。(2)取适量丙酮将待测粗浸膏充分溶解、配制成100μg/mL的样品溶液,取5mL均匀喷洒于铺有滤纸的培养皿中,使滤纸与药液充分饱和,待丙酮充分挥发后加入5mL无菌水。空白对照用丙酮作同样处理,同浓度2,4-D作为阳性对照。(3)选取刚刚露白的上述供试种子(每皿20粒)均匀置于上述处理过的滤纸-培养皿中,27℃、80%相对湿度、定时光照(12/12白天/黑夜)条件的人工气候培养箱培养4d。(4)测量幼根长度,以平均根生长抑制率表示化合物的除草活性,每个处理重复3皿。平均生长抑制率(%)=[对照平均根长-处理平均根长]/对照平均根长×100%。
如图30所示,单体化合物11和5在测定浓度为100μg/mL时能有效抑制稗草根的生长,抑制率分别达到了55.3%和41.7%,表现出良好的抑制能力;化合物6在高浓度时对稗草根生长抑制活性较弱,抑制率为6.1%,而阳性对照2,4-Dichlorophenoxyacetic acid在100μg/mL能基本抑制稗草根的生长。
Claims (4)
1.田无链霉菌(Streptomyces tanashiensis)BYF112,该菌种于2019年6月20日在中国典型培养物保藏中心保藏,菌种保藏号为CCTCC M 2019474。
2.一类生物碱化合物的制备方法,其特征在于,其制备方法包括以下步骤:
1)、将权利要求1所述的链霉菌BYF112接种到高氏培养基上,在160-200rpm,27.5~28.5℃条件下培养2~3天作为种子液;
2)、将种子液接种于高氏培养基中,在160~200rpm、27.5~28.5℃条件下发酵6.5~7.5天,即得发酵液;
3)、将步骤2)所得发酵液过滤,滤液用乙酸乙酯萃取,真空浓缩干燥,得粗浸膏;
4)、将步骤3)所得粗浸膏进行硅胶柱层析分段,采用二氯甲烷/甲醇进行梯度洗脱,所述二氯甲烷与甲醇的体积比依次为100:0、100:1、100:2、100:4、100:8;从而分别得到5个洗脱部分F1~F5;
5)、将步骤4)所得组分F2浓缩处理后,在甲醇中重结晶,得到化合物8;对所得组分F3进行同样的处理得到化合物11和组分F3-1,将组分F3-1浓缩处理后,在乙酸乙酯中重结晶分别得到化合物5和10和组分F3-1-1,将组分F3-1-1经凝胶柱层析分离,得到化合物2;对所得组分F4同样的处理得到化合物9和组分F4-1,F4-2,F4-3,F4-4,将其中组分F4-1和F4-2合并,经凝胶柱层析分离分别得到化合物1、6和7,将其中组分F4-3进行以二氯甲烷/甲醇为洗脱剂的硅胶柱分离后在甲醇中重结晶,得到化合物3,将其中组分F4-4进行以二氯甲烷/甲醇为洗脱剂的硅胶柱分离后在甲醇中重结晶,得到化合物4;所述浓缩条件为:0.1个负压的真空度,45℃;所述化合物1和2为紫红色粉末;所述化合物3、4和7为红色粉末;所述化合物5为橙黄色粉末;所述化合物6为褐色粉末;所述化合物8和10为无色晶体;所述化合物9为黄色粉末;所述化合物11为墨绿色粉末;化合物1-11分别具有如下结构式:
3.根据权利要求2所述的化合物1-11的制备方法,其特征在于,发酵培养基的成份为/L:KNO3 1g,K2HPO4·3H2O 0.5g,MgSO4·7H2O 0.5g,NaCl 0.5g,FeSO4·7H2O 0.01g,可溶性淀粉20g,H2O 1.0L,pH 7.2。
4.如权利要求2所述的制备方法得到的化合物1、2、5、6、11的用途,其特征是:其中化合物1在制备抗卵巢癌药物的应用;化合物2能制备抗人恶性黑色素瘤药物的应用;化合物5在制备抗人恶性黑色素瘤、卵巢癌、人胃癌药物的应用及抑制稗草根生长的应用;化合物6在制备抗人恶性黑色素瘤、卵巢癌、人胃癌药物的应用及抑制稗草根生长的应用;化合物11在制备抗人恶性黑色素、卵巢癌、人胃癌药物的应用及抑制四链球菌药物的应用和稗草根生长的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210562230.1A CN115491322B (zh) | 2022-05-23 | 2022-05-23 | 一类生物碱的提取方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210562230.1A CN115491322B (zh) | 2022-05-23 | 2022-05-23 | 一类生物碱的提取方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115491322A CN115491322A (zh) | 2022-12-20 |
CN115491322B true CN115491322B (zh) | 2023-11-03 |
Family
ID=84465111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210562230.1A Active CN115491322B (zh) | 2022-05-23 | 2022-05-23 | 一类生物碱的提取方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115491322B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016001410A1 (en) * | 2014-07-03 | 2016-01-07 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Use of metalloproteinase inhibitors against bacterial infections |
CN106305793A (zh) * | 2016-08-29 | 2017-01-11 | 佛山市艳晖生物科技有限公司 | 一种防治棉花黄萎病的复合微生物菌肥及其制备方法 |
CN106497981A (zh) * | 2016-10-31 | 2017-03-15 | 广东省微生物研究所 | 一种激活微生物隐性次级代谢产物生物合成基因簇表达的方法 |
US10449260B2 (en) * | 2011-07-08 | 2019-10-22 | Theodosia Maina-Nock | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
-
2022
- 2022-05-23 CN CN202210562230.1A patent/CN115491322B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10449260B2 (en) * | 2011-07-08 | 2019-10-22 | Theodosia Maina-Nock | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
WO2016001410A1 (en) * | 2014-07-03 | 2016-01-07 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Use of metalloproteinase inhibitors against bacterial infections |
CN106305793A (zh) * | 2016-08-29 | 2017-01-11 | 佛山市艳晖生物科技有限公司 | 一种防治棉花黄萎病的复合微生物菌肥及其制备方法 |
CN106497981A (zh) * | 2016-10-31 | 2017-03-15 | 广东省微生物研究所 | 一种激活微生物隐性次级代谢产物生物合成基因簇表达的方法 |
Non-Patent Citations (1)
Title |
---|
Streptomyces xinjiangensis sp. nov., an actinomycete isolated from Lop Nur region;Cong Cheng;Arch Microbiol;第198卷(第8期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN115491322A (zh) | 2022-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107353274B (zh) | 源于草酸青霉的黑麦酮酸i及制备抗人食管癌药物的应用 | |
CN107298672B (zh) | 源于草酸青霉的黑麦酮酸i在制备抗人结肠癌药物的应用 | |
CN111548954B (zh) | 四种蒽醌类化合物及其制备方法和用途 | |
CN103265550A (zh) | 一类生物碱类化合物及其制备方法和在制备抗海洋生物污损涂料与抗肿瘤药物中的应用 | |
CN115806881A (zh) | 一种青霉属真菌及其在制备抗菌药物中的应用 | |
CN115491322B (zh) | 一类生物碱的提取方法与应用 | |
CN107298669B (zh) | 源于草酸青霉的黑麦酮酸i及抗人口腔表皮样癌药物应用 | |
KR19990025976A (ko) | 세라시아 마르세센스 균주와 그 배양액에서 분리한 프로디지오신의 면역억제제로서의 용도 | |
CN110407792B (zh) | 源于草酸青霉的黑麦酮酸类化合物Secalonic acid J及制备方法 | |
CN110330544A (zh) | 一种4,4,1-双环甾类化合物及其制备方法和用途 | |
CN114452309B (zh) | 杨叶肖槿内生真菌发酵提取物及其制备方法与用途 | |
CN114380782B (zh) | 化合物及制备方法、杀菌剂在防治橡胶炭疽病中的应用 | |
CN115287236B (zh) | 一类昆虫共生放线菌来源的生物碱化合物的制备方法和用途 | |
CN102898412B (zh) | 具有抗肿瘤和抗菌活性的十二元环内酯类化合物及其应用 | |
CN112795617B (zh) | 海洋真菌次级代谢物及其制备与应用 | |
CN110407797B (zh) | 源于草酸青霉的黑麦酮酸类化合物Secalonic acid K及制备方法 | |
CN107312014B (zh) | 一种格菲罗霉素类化合物及其制备方法和应用 | |
CN109134417B (zh) | 源于草酸青霉的黑麦酮酸i及抗人子宫颈癌药物的应用 | |
Abbas et al. | Isolation and Screening of Actinomycetes producing Antibacterial compounds from different river sediments | |
CN104447475B (zh) | 源于桔青霉的青霉烯醇 d1制备方法及其应用 | |
CN113402471B (zh) | 来源于植物内生真菌的铁载体类化合物及制备方法与应用 | |
CN115650854B (zh) | 整合素衍生物及其制备方法和在α-葡萄糖苷酶抑制药物等方面的应用 | |
CN115710167B (zh) | 两个二苯醚化合物及其制备方法和在制备抗菌药物中的应用 | |
CN116375777B (zh) | 一种芳香聚酮类化合物及其制备方法和应用 | |
CN104211670A (zh) | 一种烷基吡喃酮类化合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |